OS Therapies Inc (OSTX) - Dilution Analysis

10-Q filing | 44.5M shares outstanding

8-K filing: OS Therapies Incorporated completed a registered direct offering of 2,505,073 shares of common stock and pre-funded warrants to purchase up to 1,250,893 shares, along with accompanying warrants to purchase up to 3,755,966 shares, resulting in net proceeds of approximately $4.7 million. ($4.7M proceeds)

8-K filing: OS Therapies Incorporated filed a prospectus supplement covering the resale of up to 10,529,417 shares of the Company's common stock by selling stockholders.

8-K filing: OS Therapies Incorporated entered into inducement offer letter agreements with less than 10 accredited investors to exercise existing warrants for cash at a reduced price of $1.40 per share in exchange for new warrants to purchase up to 5,382,148 shares at $1.40 per share. ($7.5M proceeds)

10-Q filing | 32.0M shares outstanding

8-K filing: OS Therapies Incorporated filed a prospectus supplement covering the resale of up to 4,373,043 shares of the Company's common stock by selling stockholders.

8-K filing: OS Therapies Incorporated closed a warrant exercise inducement and exchange offer on September 2, 2025, issuing new warrants in exchange for the exercise of existing warrants, resulting in gross proceeds of approximately $3,777,808. ($3.78M proceeds)

10-Q filing | 31.9M shares outstanding

8-K filing: OS Therapies Incorporated completed a warrant exercise inducement and exchange offer, resulting in the issuance of 3,764,995 shares of common stock for gross proceeds of approximately $4,216,794. ($4.22M proceeds)

8-K filing: OS Therapies Incorporated completed a second closing of the warrant exercise inducement and exchange offer, with holders exercising warrants to purchase 550,004 shares of common stock for $616,000, and the company issuing new warrants to purchase up to 550,004 shares at $3.00 per share. ($0.62M proceeds)

8-K filing: OS Therapies Incorporated entered into inducement offer letter agreements with holders of certain existing warrants to purchase up to an aggregate of 1,574,288 shares of the Company's common stock in consideration of the Company's agreement to issue new common stock purchase warrants to purchase up to an aggregate of 1,574,288 shares of the Company's common stock. ($8.0M proceeds)

S-1 filing: This S-1 filing registers 7,493,874 shares of common stock for resale by selling stockholders.

10-Q filing | 28.1M shares outstanding

POS AM filing: This prospectus covers up to 10,834,044 shares of common stock of OS Therapies Incorporated that may be offered for resale or otherwise disposed of by the selling stockholders.

POS AM filing: This POS AM filing discusses the effect of sales of shares under the ELOC Purchase Agreement on the company's stockholders. It details the potential dilution and market price decline risks associated with the resale of shares by the Investor, including ELOC Shares, Initial Commitment Shares, and True-Up Shares.

10-K filing | 21.7M shares outstanding

S-1 filing: This S-1 filing relates to the resale of 10,834,044 shares of common stock of OS Therapies Incorporated by selling stockholders, derived from the conversion of Series A Preferred Stock and the exercise of warrants.

8-K filing: OS Therapies Incorporated completed a second closing of a private placement, selling 263,250 units consisting of Series A Preferred Stock and warrants to purchase common stock, for gross proceeds of approximately $1,053,000. ($1.05M proceeds)

8-K filing: OS Therapies Incorporated completed a private placement, selling 1,512,500 units consisting of Series A Preferred Stock and warrants for gross proceeds of approximately $6,050,000, and entered into a Waiver and Agreement with ELOC Investor, agreeing to issue additional shares of common stock. ($6.05M proceeds)

S-1/A filing: This S-1/A filing relates to the resale of shares under an ELOC Purchase Agreement, including ELOC Shares, Initial Commitment Shares, and True-Up Shares.

S-1/A filing: The filing relates to the registration for resale of shares that may be issued and sold to an investor under an ELOC Purchase Agreement.

10-Q filing | 21.2M shares outstanding

S-1 filing: This S-1 filing relates to the resale of shares under an ELOC Purchase Agreement, where the investor may offer, sell, or distribute registered shares publicly or privately.

10-Q filing | 20.9M shares outstanding

S-1/A filing: S-1/A filing for an equity line offering of common stock at $4.00 per share, with an option for underwriters to purchase additional shares.

S-1/A filing: This S-1/A filing describes an offering of common stock at $4.00 per share, with an underwriter option to purchase additional shares. The company has applied to list its shares on the NYSE American under the symbol "OSTX." The filing also mentions the company is an emerging growth company and a smaller reporting company.

RW filing: OS Therapies Incorporated is requesting to withdraw their Post-Effective Amendment due to filing a new Registration Statement on Form S-1 (File No. 333-279839) to increase the number of securities currently registered, and confirms that no securities have been or will be issued or sold pursuant to the Post-Effective Amendment.

RW filing: OS Therapies Incorporated is withdrawing a registration statement (Form RW) filed in relation to the Company's contemplated initial public offering as a new Registration Statement on Form S-1 (File No. 333-279839) has been filed to increase the number of securities currently registered.

S-1 filing: This is an S-1 filing for an initial public offering of common stock, including an option for the underwriters to purchase additional shares and warrants to the representative of the underwriters.

10-Q filing | 11.4M shares outstanding

POS AM filing: This POS AM filing relates to an offering of common stock with a proposed price of $4.00 per share and grants a 45-day option to underwriters to purchase additional shares.

S-1/A filing: This S-1/A filing details the intended use of proceeds from a proposed offering to advance clinical development of OST-HER2 and OST-tADC, discover new product candidates, and for general corporate purposes.

S-1/A filing: This S-1/A filing details a proposed offering to raise funds for clinical development of OST-HER2 for Osteosarcoma, development of OST-tADC for ovarian cancer, discovery and development of new product candidates, and for working capital and other general corporate purposes.

S-1/A filing: This S-1/A filing outlines a public offering by OS Therapies Incorporated, with net proceeds allocated to clinical development of OST-HER2 for Osteosarcoma, development of OST-TDC for ovarian cancer, discovery of new product candidates, and general corporate purposes.

S-1/A filing: This S-1/A filing details a proposed offering to fund the clinical development of OST-HER2 for Osteosarcoma, development of OST-TDC for ovarian cancer, the discovery and development of new product candidates, and for working capital and other general corporate purposes.

S-1/A filing: The filing is an S-1/A form, detailing the use of proceeds from a proposed offering to advance the clinical development of OST-HER2 for Osteosarcoma, OST-TDC for ovarian cancer, discovery and development of new product candidates and for working capital and other general corporate purposes.